COVID-19 test

[키워드] 1:1 Administered age antibiotic antiviral efficacy Asthma Azithromycin Beta blocker blinded block calcium cardiovascular change changed chronic clinical combination therapy Control control group coordinator COPD COVID-19 COVID-19 test Day days alive death derivative Diagnosis Direct Current discharged disorder dissemination double-blind study ECG element ergot alkaloid expected Final FiO2 generate Glucose glucose-6-phosphate dehydrogenase deficiency guide hearing loss hematological hospital hospitalisation Hospitalization hospitals Hydroxychloroquine hypersensitivity impede Inclusion Informed consent intensive care Interstitial lung disease Intervention intervention group invasive ventilation investigated investigator Liver disease lung maculopathy medication mental illness modulation myasthenia gravis negative pregnancy test network Neurogenic neurological number objective offered outcome parallel group participant Patient patients with COVID-19 Placebo pregnant Primary outcome problem protocol psoriasis pulmonary QTc QTc interval randomisation randomised randomised controlled trial receive recruited recruitment reduce Registered reported respiratory infections retinopathy risk Sample size sequence significantly Sponsor Standard standard care standard treatment status Stratification Study protocol the patient therapy treated Treatment Trial Visual field website women
[DOI] 10.1186/s13063-020-04409-9 PMC 바로가기 [Article Type] Letter